Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder
3 other identifiers
interventional
30
1 country
1
Brief Summary
This study will determine the effectiveness of adding motivational interviewing to cognitive behavioral therapy, consisting of exposure and ritual prevention, in improving treatment outcomes in people with obsessive-compulsive disorder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started Mar 2006
Longer than P75 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2006
CompletedFirst Submitted
Initial submission to the registry
April 18, 2006
CompletedFirst Posted
Study publicly available on registry
April 20, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2010
CompletedMarch 16, 2012
March 1, 2012
4 years
April 18, 2006
March 15, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Obsessive-compulsive symptoms
Measured at Months 2 and 8
Secondary Outcomes (1)
Adherence, depression, insight, and quality of life
Measured at Months 2 and 8
Study Arms (2)
1
ACTIVE COMPARATORParticipants will receive motivational interviewing plus exposure and response prevention
2
ACTIVE COMPARATORParticipants will receive exposure and response prevention only
Interventions
Participants will receive 18 sessions of MI plus EX/RP.
Participants will receive 18 sessions of EX/RP.
Eligibility Criteria
You may qualify if:
- Primary diagnosis of OCD as defined by DSM-IV
- Obsessions and/or compulsions must have been present for at least one year
- At pre-treatment, a minimum on Y-BOCS on items 1-10 of 16
- If on psychiatric medication, patient has been on stable SRI dose for a minimum of 12 weeks (and four weeks for concomitant OCD meds,e.g., benzos and antipsychotics) and plans to remain on a stable dose for the duration of the EX/RP+MI treatment.
- Able to provide informed consent
- No prior adequate EX/RP treatment (defined as at least 8 exposure sessions that include response prevention instructions and between sessions assignments in a 2 month period)
- Based on hx, subject is unlikely to require a change in med during the course of EX/RP/EX/RP+MI treatment
You may not qualify if:
- Any additional medical or psychiatric conditions that could make participation in the study medically inadvisable
- Currently receiving psychotherapy at another clinic
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
New York State Psychiatric Institute
New York, New York, 10032, United States
Related Publications (1)
Farris SG, McLean CP, Van Meter PE, Simpson HB, Foa EB. Treatment response, symptom remission, and wellness in obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jul;74(7):685-90. doi: 10.4088/JCP.12m07789.
PMID: 23945445DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Helen Blair Simpson, MD, PhD
New York State Psychiatric Institute
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 18, 2006
First Posted
April 20, 2006
Study Start
March 1, 2006
Primary Completion
March 1, 2010
Study Completion
March 1, 2010
Last Updated
March 16, 2012
Record last verified: 2012-03